, INCa : Les cancers en France, édition, 2014.

. Omedit-ile-de-france, , 2015.

S. M. Swain, J. Baselga, S. Kim, J. Ro, V. Semiglazov et al.,

, Pertuzumab, trastuzumab, and docétaxel in HER2-positive metastatic breast cancer

J. Engl and . Med, , vol.372, pp.724-758, 2015.

C. A. Harris, R. L. Ward, T. A. Dobbins, A. K. Drew, and S. Pearson, The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis, Ann Oncol Off J Eur Soc Med Oncol, vol.22, issue.6, pp.1308-1325, 2011.

D. J. Slamon, B. Leyland-jones, S. Shak, H. Fuchs, V. Paton et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, vol.344, issue.11, pp.783-92, 2001.

S. Verma, D. Miles, L. Gianni, I. E. Krop, M. Welslau et al., Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, vol.367, pp.1783-91, 2012.

D. Cameron, M. Casey, M. Press, D. Lindquist, T. Pienkowski et al., A phase III randomized comparison of lapatinib plus capécitabine versus capécitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses, Breast Cancer Res Treat, vol.112, issue.3, pp.533-576, 2008.

B. Kaufman, J. R. Mackey, M. R. Clemens, P. P. Bapsy, A. Vaid et al.,

, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.33, pp.5529-5566, 2009.

J. Huober, P. A. Fasching, M. Barsoum, L. Petruzelka, D. Wallwiener et al.,

, Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptorpositive metastatic breast cancer -results of the eLEcTRA trial, Breast Edinb Scotl, 2012.

F. Cardoso, A. Costa, E. Senkus, M. Aapro, F. André et al.,

, ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3), Ann Oncol Off J Eur Soc Med Oncol, vol.28, issue.1, pp.16-33, 201701.

H. Mouridsen, M. Gershanovich, Y. Sun, R. Pérez-carrión, C. Boni et al.,

, Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal 37 women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.19, issue.10, pp.2596-606, 2001.

J. Bonneterre, B. Thürlimann, J. F. Robertson, M. Krzakowski, L. Mauriac et al., Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, issue.22, pp.3748-57, 2000.

R. J. Paridaens, L. Y. Dirix, L. V. Beex, M. Nooij, D. A. Cameron et al., Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.30, pp.4883-90, 2008.

M. Crump, C. A. Sawka, G. Deboer, R. B. Buchanan, J. N. Ingle et al., An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer, Breast Cancer Res Treat, vol.44, issue.3, pp.201-211, 1997.

J. G. Klijn, R. W. Blamey, F. Boccardo, T. Tominaga, L. Duchateau et al.,

, Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials, J Clin Oncol Off J Am Soc Clin Oncol, vol.19, issue.2, pp.343-53, 2001.

J. Robertson, A. Llombart-cussac, J. Rolski, D. Feltl, J. Dewar et al.,

, Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study, J Clin Oncol Off J Am Soc Clin Oncol, 2009.

J. Baselga, M. Campone, M. Piccart, H. A. Burris, H. S. Rugo et al.,

, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, vol.366, issue.6, pp.520-529, 2009.

A. Dufresne, X. Pivot, C. Tournigand, T. Facchini, T. Altweegg et al., Impact of chemotherapy beyond the first line in patients with metastatic breast cancer, Breast Cancer Res Treat, vol.107, issue.2, pp.275-284, 2008.

T. Byrski, T. Huzarski, R. Dent, J. Gronwald, D. Zuziak et al., Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients, Breast Cancer Res Treat, vol.115, issue.2, pp.359-63, 2009.

D. P. Silver, A. L. Richardson, A. C. Eklund, Z. C. Wang, Z. Szallasi et al., Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.7, pp.1145-53, 2010.

C. H. Van-poznak, V. Roenn, J. H. Temin, and S. , American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer, J Oncol Pract, vol.7, issue.2, pp.117-138, 2011.

E. Gobbini, M. Ezzalfani, V. Dieras, T. Bachelot, E. Brain et al., Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
URL : https://hal.archives-ouvertes.fr/hal-01930014

A. M. Gonzalez-angulo, F. Morales-vasquez, and G. N. Hortobagyi, Overview of resistance to systemic therapy in patients with breast cancer, Eur J Cancer Oxf Engl, vol.96, pp.1-22, 1990.

M. Colozza, E. De-azambuja, N. Personeni, F. Lebrun, M. J. Piccart et al.,

, Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. The Oncologist, vol.12, pp.253-70, 2007.

L. Oostendorp, P. Stalmeier, A. Donders, W. Van-der-graaf, and O. ,

. Pb, Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review, Lancet Oncol, 2011.

A. Moreno-aspitia and E. A. Perez, Treatment options for breast cancer resistant to anthracycline and taxane, Mayo Clin Proc, vol.84, issue.6, pp.533-578, 2009.

R. F. Dear, K. Mcgeechan, M. C. Jenkins, A. Barratt, M. Tattersall et al.,

, Combination versus sequential single agent chemotherapy for metastatic breast cancer

, Cochrane Database Syst Rev, issue.12, p.8792, 2013.

E. Andreopoulou and J. A. Sparano, Chemotherapy in Patients with Anthracycline-and

. Taxane-pretreated, Metastatic Breast Cancer: An Overview. Curr Breast Cancer Rep, 2013.

, Mar, vol.1, issue.1, pp.42-50

A. Güntner, M. Pauligk, C. Scholz, M. Chen, R. Beiss et al.,

, Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials, Br J Cancer, vol.103, issue.10, pp.1518-1541, 2009.

M. Toulmonde, N. Madranges, V. Brouste, C. Donamaria, G. Macgrogan et al.,

, Docétaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity, Breast Cancer Res Treat, 2012.

F. Cardoso, N. Harbeck, L. Fallowfield, S. Kyriakides, and E. Senkus, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.23, issue.7, pp.11-19, 2012.

C. M. Walko and C. Lindley, Capécitabine: a review, Clin Ther, vol.27, issue.1, pp.23-44, 2005.

L. Jones, N. Hawkins, M. Westwood, K. Wright, G. Richardson et al., Systematic review of the clinical effectiveness and cost-effectiveness of capécitabine (Xeloda) for locally advanced and/or metastatic breast cancer, Health Technol Assess Winch Engl, vol.8, issue.5, pp.1-143, 2004.

K. D. Miller, L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom et al.,

, Randomized phase III trial of capécitabine compared with bevacizumab plus capécitabine in patients with previously treated metastatic breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.4, pp.792-801, 2005.

E. S. Thomas, Ixabepilone plus capécitabine for metastatic breast cancer progressing after anthracycline and taxane treatment, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.13, p.2223, 2008.

M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller et al., The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth, Mol Cancer Ther, vol.4, issue.7, pp.1086-95, 2005.

T. Okouneva, O. Azarenko, L. Wilson, B. A. Littlefield, and M. A. Jordan, Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase, Mol Cancer Ther, 2008.

J. A. Smith, L. Wilson, O. Azarenko, X. Zhu, B. M. Lewis et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability, Biochemistry, vol.49, issue.6, pp.1331-1338, 2010.

L. T. Vahdat, B. Pruitt, C. J. Fabian, R. R. Rivera, D. A. Smith et al., Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.18, pp.2954-61, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01440451

J. Cortes, L. Vahdat, J. L. Blum, C. Twelves, M. Campone et al., Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capécitabine, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.25, pp.3922-3930, 2010.

K. Aogi, H. Iwata, N. Masuda, H. Mukai, M. Yoshida et al., A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer, Ann Oncol Off J Eur Soc Med Oncol, vol.23, issue.6, pp.1441-1449, 2012.

J. Cortes, J. O'shaughnessy, D. Loesch, J. L. Blum, L. T. Vahdat et al.,

, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet Lond Engl, vol.377, issue.9769, pp.914-937, 2011.

P. A. Kaufman, A. Awada, C. Twelves, L. Yelle, E. A. Perez et al.,

, Conformément à la règlementation portant sur les recherches n'impliquant pas la personne humaine (recherche sur données existantes), le Promoteur de l'étude, le Centre François Baclesse, ayant fait l'objet d'une déclaration de mise en conformité à la MR-003

, données à caractère personnel et modifiant la loi n° 78-17 du 6 janvier 1978 modifiée le 22/01/2017 relative à l'informatique, aux fichiers et aux libertés

, Vous êtes libre d'accepter ou de refuser de participer à cette étude

, Si vous décidez de ne pas autoriser l'utilisation de vos données médicales, votre médecin continuera de vous soigner et d'assurer votre surveillance sans que vos relations soient modifiées

, Si vous avez des questions concernant cette étude, vous pouvez vous adresser au Dr Levy qui pourra être contacté au n° de téléphone suivant : En cas d'opposition de votre part à l'utilisation de vos données personnelles, merci de nous en informer par retour de courrier à l'aide du coupon réponse ci-joint afin que vos données médicales ne